COVID-19 Vaccine Only Hope Fails to Produce Efficacy As Practiced Treatments
The SARS-Cov-2 virus, dubbed COVID-19, is still in its edge over humans almost a year after its invasion worldwide, which is not shocking given the unprecedented crisis triggered by a virus which is unknown to hardly anyone, its apparently chosen approach to mildness or seriousness of infection, distressing both medical scientists and physicians.
Humanity, in its very advanced stage, is never a party to defeat and, as such, an efficient vaccine is constantly being pursued, and research on antiviral or anti-malarial medicines, plasma therapy and other treatment methods has meanwhile been deliberately undertaken.
The key issue is that the death rate should at least be decreased, which vary even from one country to the next, and it is now known that there is no cure for this disease.
Diverse vaccine initiatives in different stages of development in different countries are underway, most of which pledge a new year vaccine or the start of next year. Now, the most important question has been raised by the current disappointing advances in treatment strategies practised so far: is an successful vaccine just hope for humanity?
Most of us recall when the pandemic raged furiously in Europe and the US, the desperate foreign craving for an essentially Indian anti-malarial drug named Hydroxychloroquine (HCQ) and the US President going to the point of threatening India if supplies of HCQ were not.
Slowly, however, this medication was found ineffective over time and even a little harmful with respect to natural immunity. Then, with apparently promising outcomes, several other medications and steroids were used, Remdesivir being the one most accepted as a life-saver.
The findings of the Solidarity Clinical Trial, one of most promising international Randomized Controlled Trials (RCTs) since March 2020, have been recently declared as unsuccessful in reducing mortality by the World Health Organization (WHO). It was found that the four treatment strategies tested, HCQ, Remdesivir, Lopinavir or Ritonavir, and Interferon, had little or no effect on mortality rates.
There have always been questions about their results with respect to the RCTs conducted in different countries of the world, including China, and experts feel the need for more such studies. With respect to its sampling methods from different quarters, concerns were also raised against the Solidarity Trial, with one Indian hospital refusing to stop using Remdesivir citing its benefits to its patients over the months.
More deceptive news came from the Indischen Rat der Medical Research (ICMR), which has so far allowed research therapy in progressive stages of the disease in India to remove blood plasma from recovered COVID-19 patients and to inject the antibody-rich extract to the positive patients , especially the more seven
The Indian Council of Medical Research (ICMR), It was built over the months into a comprehensive treatment method that produced adequate donation networks across the states as infected doctors have made it a point to donate the precious plasma.
On 20 October 2020, the Director-General of the ICMR announced the results after carrying out its own RCT during the period from April to July of the year, covering more than 400 hospitals in the country’s 39 medical centres. Based on the findings, the ICMR concluded that the CPT does not minimise the mortality rate or prevent the progression of moderate-t COVID-19 infections.
The government of India has demanded the elimination of CPT from its COVID-19 national clinical management protocol, according to this conclusions. This is also sad news as, in the absence of an effective vaccine, CPT has been a very common COVID-19 treatment tool.
However, experts are not persuaded of the findings of the CPT, saying it could have had to do with the delay in infusion and the consistency of the antibodies. Internationally, the CPT continues to be a form of treatment intended only for use in an emergency. Anyway, the value of discovering an appropriate vaccine increases even more in view of all these results.
The pandemic is still far from keeping its clutches away from humanity: India finally hit its height in the third week of September 2020 after more than six months of haphazard acceleration, with new cases still hovering about fifty thousand a day and 500 + daily deaths, while the European countries and the US are experiencing a second surge.
Chinmay Chakravarty is a creative specialist who has over two decades of experience in the fields of journalism, media coordination, the writing of scripts, film dubbing, film & video production, international film Festival management and book & journal editing.
Professional services in these regions. Professional services. He was an Indian Info Service Officer and superannuated from November 2019 as Director of the Press Office in Kolkata. His first solo book was released in 2017, ‘Laugh and Let Laugh.’